Psychiatry
Market Access/ News/ News/ News/ Sales and Marketing
AbbVie claims key approval for Vraylar in depression
Phil Taylor
AbbVie, depression, Psychiatry, regulatory approval, Vraylar
0 Comment
News/ News/ News/ R&D/ Sales and Marketing
J&J builds case for antidepressant Spravato with head-to-head trial
Phil Taylor
depression, Janssen, Johnson & Johnson, Psychiatry, Spravato
0 Comment
Largest-ever trial backs psilocybin treatment for depression
Phil Taylor
Compass Pathways, depression, psilocybin, psychedelics, Psychiatry
0 Comment
Digital/ News/ News/ News/ R&D
Could cancer be diagnosed from the sound of a voice?
Phil Taylor
cancer, diagnostic, digital, digital health, neurology, Owkin, Psychiatry, vocal biomarkers
0 Comment
Axsome bounces back as FDA clears depression drug
Phil Taylor
Auvelity, Axsome Therapeutics, depression, Johnson & Johnson, Psychiatry, regulatory approval, Spravato
0 Comment
Digital/ Market Access/ News/ News/ News
NICE backs AliveCor’s smartphone-linked ECG for NHS use
Phil Taylor
AliveCor, diagnostics, digital, digital health, ECG, NHS, NICE, Psychiatry
0 Comment
Sosei Heptares banks $30m milestone in Neurocrine Bio alliance
Phil Taylor
Karuna Therapeutics, Neurocrine Biosciences, partnering, Psychiatry, schizophrenia, Sosei Heptares
0 Comment
VistaGen’s horizons may shrink after clinical trial setback
Phil Taylor
central nervous system, Psychiatry, social anxiety disorder, VistaGen Therapeutics
0 Comment